Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.55 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.55 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 2/20 | 0.46 |
| ▸ | MPO | P05164 | 2/20 | 0.45 |
| ▸ | CLEC4M | Q9H2X3 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | MAPT | P10636 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1420103 | 0.93 | SMN1; SMN2 (0.51) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1420923 | 0.82 | HTT (0.54) | SMN1; SMN2HTTMPOCLEC4MALDH1A1 | |
| SCHEMBL10300666 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL597473 | 0.79 | SMN1; SMN2 (0.66) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1420944 | 0.77 | HTT (0.46) | SMN1; SMN2CYP1A2CYP2D6CYP2C19HTT | |
| SCHEMBL1420670 | 0.76 | SMN1; SMN2 (0.42) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1420616 | 0.76 | SMN1; SMN2 (0.40) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7399266 | 0.75 | SMN1; SMN2 (0.92) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL2133804 | 0.75 | CYP4F2 (0.47) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL1420320 | 0.74 | CYP4F2 (0.38) | SMN1; SMN2CYP1A2CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8217028-B2 | 1,2,4-oxadiazole indole compounds | GLAXO GROUP LIMITED (GB) | 2012-07-10 | — | — | US | disclosed |
| US-20110086839-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2011-04-14 | — | — | US | disclosed |
| EP-2297139-A1 | COMPOUNDS | Glaxo Group Limited (GB) | 2011-03-23 | — | — | EP | disclosed |
| US-20100029729-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-02-04 | — | — | US | disclosed |
| US-20100010053-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2010-01-14 | — | — | US | disclosed |
| WO-2009153307-A1 | COMPOUNDS | GLAXO GROUP LIMITED (GB) | 2009-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029729-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | SMN1; SMN2 889/4885CYP1A2 18/4885CYP3A4 13/4885 |
| US-20100010053-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | SMN1; SMN2 889/4885CYP1A2 18/4885CYP3A4 13/4885 |
| US-20110086839-A1 | COMPOUNDS | CYP11B2, CYP11B1, GLS2 | SMN1; SMN2 889/4885CYP1A2 18/4885CYP3A4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.